CD8A and neoplasm: Similar effects were observed in this preclinical study, as ATRC-101 increased ISG expression in tumors, decreased cDC2 cells, increased cDC1 cells in the blood, drove a shift in macrophages toward the M1 phenotype in tumor, and required CD8+ T cells for antitumor activity.